1. Denmark Stocks

  2. •

    Healthcare

  3. •

    Medical - Healthcare Information Services
Monsenso A/S

Monsenso A/S

MONSO.CO
Monsenso A/SDK flagNASDAQ Copenhagen
0.30
DKK
-0.06
- -
20.03MMarket Cap
Monsenso A/S
MONSO.CO
(NASDAQ Copenhagen)

Recent

price

0.30

P/E

ratio

- -

div

yld

- -

ROIC.AI

2017
2018
2019
2020
2021
2022
2023
2024
2025
FRC
1.79
2.09
2.44
0.65
0.29
0.23
0.31
0.17
- -
Revenue per Share
-0.94
-0.58
-0.06
-0.34
-0.34
-0.29
-0.18
-0.09
- -
Basic EPS, GAAP
- -
-1.26
-0.36
-0.13
-0.64
-0.31
-0.01
-0.14
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
0.03
-0.63
-0.31
1.33
0.88
0.55
0.35
0.21
- -
Book Value per Share
-1.08
-1.28
-0.91
0.57
0.25
-0.04
-0.1
0.04
- -
Tangible Book Value per Share
4
4
4
14
24
27
31
67
- -
Basic Weighted Avg Shares
6
8
9
9
7
6
10
11
9
Sales/Revenue/Turnover
-63.69
-27.63
1.9
-64.81
-126.29
-141.9
-60.26
-58.05
-85.12
Operating Margin (%)
1
2
2
4
4
5
4
4
5
Depreciation Expense
-3
-2
- -
-5
-8
-8
-5
-6
-7
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
-52.33
-27.82
-2.56
-52
-114.14
-126.41
-55.66
-53.75
-81.03
Profit Margin (%)
2
- -
-3
8
6
-1
-3
3
- -
Working Capital
4
4
3
- -
- -
- -
- -
- -
2
LT Debt
5
4
4
19
21
15
11
14
7
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
-40.78
-43.53
-41.99
-48.16
-68.65
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
-12.61%
-50.75%
Free Cash Flow
- -
891.3%
-61.21%
Net Income, GAAP
- -
13.96%
20.26%
Sales/Revenue/Turnover
- -
3.3%
-20.22%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
10
2024
- -
- -
- -
- -
11
2025
- -
- -
- -
- -
9

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
-0.18
2024
- -
- -
- -
- -
-0.09
2025
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
Similar Companies
Craneware plc (CRWRF)
HealthBeacon plc (HBCNF)
Parallax Health Sciences, Inc. (PRLX)
FINDEX Inc. (3649.T)
Inventurus Knowledge Solutions Ltd. (IKS.NS)
Imaging Biometrics Ltd. (IQAIF)
Business
Monsenso A/S develops and sells a digital health solution for remote patient monitoring, treatment support, and research in mental healthcare, focusing on conditions including depression, bipolar disorder, anxiety, schizophrenia, borderline personality disorder, addiction, and substance abuse. The company offers a CE-marked Class 1 medical device platform comprising a patient app for self-assessments, questionnaires, sensor data collection from smartphones and wearables, medication reminders, visualizations, motivational feedback, psychoeducation, cognitive behavioral therapy modules, and secure messaging; a carer app providing self-assessments, psychoeducation, and learning tools; a clinical web portal enabling patient data visualization, dashboards, historical overviews, correlation analysis, medical record keeping, messaging, and shared decision-making; and data analytics tools for historical data aggregation, statistical analysis, pattern recognition, predictive mood forecasting, and risk assessment. Founded in 2013 and headquartered in Frederiksberg, Denmark, Monsenso A/S operates primarily in Europe, serving patients, clinicians, carers, healthcare systems, social care organizations, pharmaceutical companies, insurers, private providers, and researchers through scalable SaaS subscriptions. In 2024, the company achieved 16% revenue growth to DKK 11.2 million, with 66% growth in commercial subscription revenues, alongside successful advancements in innovation projects such as PhaseV patient inclusions, upcoming Personae and MentBest studies, and new platform features including self-sign-up, e-consenting, dark mode, wearable integrations, video capabilities, and gamification.